TY  - BOOK
AU  - Mir,Manzoor Ahmad
TI  - Developing Costimulatory Molecules for Immunotherapy of Diseases
SN  - 9780128026755
AV  - RM275 
U1  - 616.079 
PY  - 2015///
CY  - San Diego
PB  - Elsevier Science & Technology
KW  - Immunity
KW  - Immunology
KW  - Immunotherapy
KW  - Electronic books
N1  - Front Cover -- Developing Costimulatory Molecules for Immunotherapy of Diseases -- Copyright Page -- Dedication -- Contents -- About the Editor -- Preface -- Acknowledgments -- 1 Introduction to Costimulation and Costimulatory Molecules -- Introduction -- Costimulatory Molecules -- Two-Signal Model of T-cell Activation -- The B7 Family of Costimulatory Ligands -- CD80 Costimulatory Molecule -- CD86 Costimulatory Molecule -- CD80 and CD86 Expression Kinetics -- CD80 and CD86 Binding Kinetics to CD28 and CTLA-4 -- Different Oligomeric States of CD80 and CD86 -- PD-L1/B7-H1 Costimulatory Molecule -- B7-H2/B7RP-1/LICOS Costimulatory Molecule -- B7-DC/PD-L2 Costimulatory Molecule -- B7-H3 Costimulatory Molecule -- B7-H4 or B7x/B7S1 Costimulatory Molecule -- CD28 Molecule -- CTLA-4 Molecule -- ICOS Molecule -- The Programmed Death-1 -- CD40 Costimulatory Molecule -- CD40L/CD154 Costimulatory Molecule -- Pathways in the TNFR/TNF Family -- 4-1BB/4-1BBL -- OX40/OX40L -- HVEM/LIGHT -- ICOS, GITR, and CD27/CD70 -- Summary -- References -- 2 Concept of Reverse Costimulation and Its Role in Diseases -- Introduction -- Concept of Bidirectional Costimulation -- Reverse Costimulation of APCs -- Role of CD80 and CD86 in the Costimulation of B Cells -- Role of Bidirectional Costimulation in the Activation of DCs -- Role of Reverse Costimulation on Macrophages -- Application of Reverse Costimulation in Diseases -- Reverse Costimulation Through CD80 (B7-1) -- Reverse Costimulation Through CTLA-4 -- B7-DC Reverse Costimulation -- Reverse Costimulation Through CD40L/CD40 -- Reverse Signaling Through CD137L/CD137 -- Role of Reverse Costimulation in Cancer -- References -- 3 Costimulation Immunotherapy in Infectious Diseases -- Introduction -- Costimulation Biology Modulation by Pathogens -- Modulation of Costimulatory Molecules by Viruses; Modulation of Costimulatory Molecules by Bacteria -- Modulation of Costimulatory Molecules by Protozoan Parasites -- Costimulatory Molecules in Therapeutic Vaccination -- Therapeutic Vaccination Using Costimulatory Molecules in HIV -- B7 Costimulatory Molecules in Infectious Diseases -- Costimulatory Molecules in Allergies and Asthma -- Involvement of the B7:CD28 Family Molecules in the Regulation of Allergic Diseases -- Regulation of the Immune Responses to Pathogens Through Costimulatory Molecules -- Expression of Coinhibitory Molecules on Effector T Cells -- Role of Coinhibitory Molecules in the Contraction of the Effector Phase of Immune Responses -- Functional Exhaustion and Loss of Effector Functions -- Potential Therapeutic Applications of Costimulatory Molecules in Infections -- Summary -- References -- 4 Costimulation Immunotherapy in Allergies and Asthma -- Introduction -- Immunology of Allergy and Asthma -- Pathophysiology of Asthma -- Response to Allergens in Asthma -- Phenotypic Variability in Asthma -- Role of Mast Cells in Allergy and Asthma -- Immunotherapy to Allergens -- Subcutaneous IT -- Sublingual IT -- Experimental IT Approaches -- Peptide-Based Therapies -- Allergen-Specific Therapy with Th1-Stimulating Adjuvants -- Novel Approaches to Allergen-SIT -- Current Immunomodulatory Strategies for Asthma Under Investigation -- Monoclonal Anti-IgE Antibody Therapy -- IgE-Binding Receptors -- Anti-IgE Monoclonal Antibodies -- sIL-4R Therapy -- Targeting Tregs for IT of Allergy and Asthma -- Costimulation in Allergy and Asthma -- Costimulation in Asthma -- Costimulation and T-Cell Reactivity to Allergens -- What Makes Costimulatory Molecules a Promising Target in Allergy and Asthma? -- T-Cell Specificity -- Expression on T Cells -- Predominant Involvement in Secondary Immune Reactions -- Positive Regulatory Signal -- Th2 T-Cell Bias; Targeting Costimulatory Molecules for Treatment of Allergen-Induced Airway Inflammation -- Targeting B7-CD28 Costimulatory Pathway -- Targeting PD-1, PD-L1/PD-L2 Costimulatory Pathway -- Targeting ICOS -- Targeting OX40 -- Targeting BTLA-4 -- Tools for Modulation of Costimulatory Signals -- Administration of Immune Modulators -- Blockade Versus Elimination of Allergen-Specific T Cells -- References -- 5 Costimulation in Lymphomas and Cancers -- Introduction -- Major Costimulatory and Coinhibitory Pathways in Antitumor Immunity -- Targeting T Cell Costimulatory Molecules to Improve Antitumor Immunity -- B7 Superfamily of Costimulatory Molecules in Antitumor Immunotherapy -- B7-1/B7-2:CD28/CTLA-4 -- CD80 in Lymphoma Growth Inhibition -- Costimulation Through CD80 in Immunity Against Cancer -- CD80 Gene Transfection of Tumor Cells to Generate Vaccine and Elicitation of Antitumor Response -- Costimulatory Monoclonal Antibodies in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia -- Anti-CD80 Antibody in Treatment of Lymphoma Patients -- Fully Humanized Anti-CTLA-4 Antibody in Treatment of Tumors -- Ipilimumab (Fully Humanized Anti-CTLA-4 Antibody) in the Treatment of Tumors -- Tremelimumab (Fully Humanized Anti-CTLA-4 Antibody) in the Treatment of Tumors -- ICOS-L:ICOS Costimulatory Pathway -- PD-L1/PD-L2:PD-1 Costimulatory Pathway -- CD279 (PD-1), CD274 (PD-L1), and CD273 (PD-L2) Expression in Malignancy -- Therapeutic Modulation of PD-1 (CD274), PDL-1 (CD279), and PDL-2 (CD273) -- HVEM:BTLA/CD160 Costimulatory Pathway -- B7-H3 and B7-H4 Costimulatory Pathway -- TNF:TNFR Superfamily of Costimulatory Molecules in Antitumor Immunity -- CD40L:CD40 Costimulatory Pathway -- 1BBL:4-1BB Costimulatory Pathway -- OX40:OX40L Costimulatory Pathway -- Light: HVEM Costimulatory Pathway -- CD70:CD27 Costimulatory Pathway -- GITRL:GITR Costimulatory Pathway; CD30L:CD30 Costimulatory Pathway -- Costimulation Immunotherapy and Tumor Tolerance -- Modulation of B7 Pathway to Augment Cancer Immunotherapy -- Allogenic HSCT -- Tumor Vaccination Strategies -- Bioengineering of T Cells for Cancer Immunotherapy -- ICOS and B7-H2 Costimulatory Pathway in Cancer -- Therapeutic Modulation of ICOS/ICOS-L -- Combination of Costimulatory Antibody-Ligand Fusion Proteins for Targeted Cancer Immunotherapy -- Summary and Conclusion -- References -- 6 T-Cell Costimulation and Its Applications in Diseases -- Introduction to T-Cell Costimulation -- Costimulation Mediated by CD28 Costimulatory Pathway in T Cells -- CD28 Costimulation Enhances T-Cell Survival -- CD28 T-Cell Costimulation in Diseases -- CD28 Costimulation in Primary T-Cell Responses -- CD28-B7 Costimulation and Its Effect on CD8+ Memory T-Cell Responses -- The Future Prospectus -- Concluding Remarks -- Unanswered Questions -- Promoting T-Cell Function by Modulating Costimulation or Co-inhibition -- Turning on the Stimulators: Antibodies to 4-1BB (CD137), OX40 (134), GITR, and CD40 -- Turning Off the Brakes: Antibodies Against CTLA-4 (CD152), PD-1 (CD279), and PD-L1 -- Adoptive T-Cell Transfer -- Improving Signaling Capacities-Second- and Third-Generation CARs -- First-Generation CARs -- Second-Generation CARs -- Third-Generation CARs -- CAR T Cells in Clinical Trials -- References -- Index
N2  - Developing Costimulatory Molecules for Immunotherapy of Diseases highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy using either humanized antibodies against CD80, CD86, and other costimulatory molecules or CD28 fusinogenic proteins in the treatment of diseases, including allergies, asthma, rheumatoid arthritis, multiple sclerosis, lupus nephritis, severe psoriasis, vulgaris tuberculosis, thopoid, transplantation therapeutic, cancer, and inflammation. The text aims to provide the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families, with the hope that targeting these families will yield new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases. Highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy Provides the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families Targets new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases
UR  - https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=2057722
ER  -